CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) Study

CEASAR (Comparative Effectiveness Analyses of Surgery and Radiation in localized prostate cancer) Study

JOURNAL ARTICLES BY YEAR OF PUBLICATION

Click PubMed ID for copyright-compliant access to publications via UC-elinks

1996

1997

1998


1999


2000


Comment Urology. 2001 Feb;57(2):394-5. PMID: 11246646


15. Lubeck DP, Litwin MS, Henning JM, Mathias SD, Bloor L and Carroll PR. An instrument to measure patient satisfaction with healthcare in an observational database: Results of a validation study using data from CaPSURE. *Am J Manag Care.* 2000 Jan;6(1):70-76. PMID: 11009748
2001


2002


2003


32. Cooperberg MR, Grossfeld GD, Lubeck DP, and Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. *J Natl Cancer Inst.* 2003 Jul 2;95 (13):981-989. *This paper has been cited over 100 times since publication. PMID: 12837834*


41. Latini DM, Downs TM, Grossfeld GD, Lubeck DP, Mehta SS and Carroll PR. Disease recurrence after radical prostatectomy for patients with high-risk disease: Data from CaPSURE and UCSF. *Amer J of Urol Rev.* 2003;1:62-71. [Request article from jcowan@urology.ucsf.edu]


2004

45. Arredondo SA, Downs TM, Lubeck DP, Pasta DJ, Silva, SJ, Wallace KL and Carroll PR. Watchful waiting and health related quality of life for patients with localized prostate cancer: Data from CaPSURE. *J Urol.* Nov;172(5 Pt 1):1830-4. *This paper was featured for CME credits.* PMID: 15540732


49. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, Carroll PR and the CaPSURE Investigators. The contemporary management of prostate cancer in the United States: Lessons from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a national disease registry. *J Urol*. 2004 Apr;171(4):1393-401. *This paper has been cited over 100 times since publication.* PMID: 15017184


2005


60. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, DuChane J, Carroll PR. The University of California, San Francisco cancer of the prostate risk assessment score: A


63. Kane CJ, Bassett WW, Sadetsky N, Silva S, Wallace K, Pasta DJ, Cooperberg MR, Chan JM, Carroll PR. Obesity and prostate cancer clinical risk factors at presentation: Data from CaPSURE. *J Urol.* 2005 Mar;173(3):732-6. This paper was featured for CME credits. PMID: 15711258


2006


2008


118. Wu AK, Cooperberg MR, Sadetsky N, Carroll PR. Health Related Quality of Life in Patients Treated with Multimodal Therapy for Prostate Cancer. *J Urol.* 2008 Dec;180(6):2415-22; discussion 2422. PMID: 18930279

2009


2010


134. Moses KA, Paciorek AT, Penson DF, Carroll PR, Master VA. Impact of Ethnicity on Primary Treatment Choice and Mortality in Men With Prostate Cancer: Data From CaPSURE. *J Clin Oncol.* 2010 28(6):1069-74. PMID: 20100957


2011


147. Reese AC, Fradet V, Whitson JM, Davis CB, Carroll PR. Poor agreement of prostate specific antigen doubling times calculated using ultrasensitive versus standard prostate specific antigen values: important impact on risk assessment. *J Urol.* 2011;186(6):2228-32. PMID: 22014796


2012


2013


2014


2015


   Reply to letter to the editor PMID: 26547474


2016

2017


2018


2019


**CEASAR papers**


quality of life outcomes, patient satisfaction, and treatment-related complications. *Med Care.* 2016 Aug;54(8):738-44. PMID: 27219634

**Related papers**


